Ibogaine molecule:

Image from PubChem

Ibogaine Clinical Trials


CYP2D6 and the pharmacokinetics of ibogaine


To see complete record on anzctr.org.au, please visit this link

Id: ACTRN12613000324718

Organisation Name: University of Otago

Overal Status: Completed

Start Date: 01/05/2013

Brief Summary: Since 1962 a network of lay experimental drug users have reported that ibogaine at high doses decreases opioid withdrawal symptoms in opioid dependent subjects. It is likely that the majority of the effects of ibogaine in humans are produced by the metabolite noribogaine rather than ibogaine itself. The conversion of ibogaine into noribogaine is mainly via an enzyme called CYP2D6. This enzyme belongs to the cytochrome P450 family and is involved in the metabolism of many drugs in the body. The study aims to characterize conversion of ibogaine to noribogaine based on measures of CYP2D6 activity, using single low doses of ibogaine dosed to healthy volunteers.

Countries:
  • New Zealand


Total execution time in seconds: 0.083073854446411